Current therapies are inadequate with issues of cost, toxicity, practicality and availability. New drugs for all diseases require new drug targets, however the identification and validation of these is fraught with difficulty and expensive failure. Recognizing that leishmaniasis and Chagas disease demand the highest quality attention, our Network is meeting the challenges of drug target validation head on through multidisciplinary research, training and capacity building.
Neglected Tropical Diseases (NTDs) are a spectrum of 18 infectious diseases of the developing world, together affecting more than 1 billion of the world’s most deprived people and exerting a greater burden than malaria, tuberculosis and HIV combined. Despite significant gains elsewhere, the battles against the protozoan NTDs, leishmaniasis and Chagas disease, are being lost – with increasing cases and mortality.